Watch NIKA. Know when insiders buy.
One email the day a filing lands. Free.
NIKA
NIKA PHARMACEUTICALS, INC
0.41
+0.00 +0.00%
USD · close Sep 22
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
50
WATCH · shorts 50
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $431.2MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$78KNET DEBT $99K52W 0.20 – 0.77SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$20K | −$20K | — | 0.00 | −$8K | — | — | Aug 10 |
| Q1 2026 · Mar 31 | — | — | — | −$13K | −$13K | — | 0.00 | −$13K | — | — | May 12 |
| Q4 2025 · Dec 31derived | — | — | — | −$37K | −$37K | — | 0.00 | −$39K | — | — | Mar 25 |
| Q3 2025 · Sep 30 | — | — | — | −$8K | −$8K | — | 0.00 | −$9K | — | — | Nov 7 |
| Q2 2025 · Jun 30 | — | — | — | −$18K | −$18K | — | 0.00 | −$19K | — | — | Aug 10 |
| Q1 2025 · Mar 31 | — | — | — | −$13K | −$13K | — | 0.00 | −$13K | — | — | May 12 |
| Q4 2024 · Dec 31derived | — | — | — | −$12K | −$12K | — | 0.00 | −$28K | — | — | Mar 25 |
| Q3 2024 · Sep 30 | — | — | — | −$8K | −$8K | — | 0.00 | −$8K | — | — | Nov 7 |
| Q2 2024 · Jun 30 | $156 | — | — | −$22K | −$22K | — | 0.00 | −$34K | — | — | Aug 14 |
| Q1 2024 · Mar 31 | — | — | — | −$46K | −$46K | — | 0.00 | −$84K | — | — | May 13 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$7K | −$7K | — | 0.00 | −$7K | — | — | Mar 31 |
| Q3 2023 · Sep 30 | $0 | — | — | −$10K | −$10K | — | 0.00 | −$10K | — | — | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$76K | −$76K | — | 0.00 | −$80K | — | — | — | — |
| FY2024 · to Dec 31 | $0 | — | −$96K | −$96K | — | 0.00 | −$155K | — | — | — | — |
| FY2023 · to Dec 31 | $0 | — | −$65K | −$65K | — | 0.00 | −$65K | — | — | — | — |
| FY2022 · to Dec 31 | $0 | — | −$3.2M | −$3.2M | — | 0.00 | $34K | — | — | — | — |
| FY2021 · to Dec 31 | $0 | — | −$15K | −$15K | — | 0.00 | $15K | — | — | — | — |
| FY2020 · to Dec 31 | — | — | −$9K | −$9K | — | 0.00 | −$9K | — | — | — | — |
Every number comes from NIKA PHARMACEUTICALS, INC's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.